| 产品描述： | SEC inhibitor KL-2 (KL-2), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-2 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 1.50 μM |
| 靶点： |
SEC |
| 体内研究： |
SEC inhibitor KL-2 (10 mg/kg，腹腔注射，每日一次，共 15 天) 在 MDA231-LM2 异种移植肿瘤裸鼠模型中延缓了肿瘤生长并延长了其生存期。 |
| 参考文献： |
1. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779. |
| 溶解性： |
soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.996 ml |
14.982 ml |
29.963 ml |
| 5 mM |
0.599 ml |
2.996 ml |
5.993 ml |
| 10 mM |
0.3 ml |
1.498 ml |
2.996 ml |
| 50 mM |
0.06 ml |
0.3 ml |
0.599 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京